Cipla invests $16-M in Germany's Ethris for mRNA-based inhalation therapies

Publicly listed pharma company Cipla, via its wholly owned subsidiary Cipla (EU) Limited, United Kingdom,, is to invest EUR 15 million (about USD 16.1 million) to acquire a 10.35% stake in Germany-based Ethris, a global player in delivering mRNAs directly to the respiratory system including administration by inhalation. The target company had reported a turnover of EUR 5.45 million for the year ended December 2021 (down from EUR 16.82 million in the year ended December 2020) The investment will enable Cipla to provide access to solutions developed by Ethris in developing countries. The transaction is expected to be completed within 60 days from the date of signing of the agreement.